EUCTR2014-004932-20-PL
Active, not recruiting
Phase 1
A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066/ABBV-066 (risankizumab) as add-on therapy over 24 weeks in patients with severe persistent asthma.
Boehringer Ingelheim RCV GmbH & CoKG0 sites200 target enrollmentStarted: August 11, 2015Last updated:
Overview
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Boehringer Ingelheim RCV GmbH & CoKG
- Enrollment
- 200
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1\. Pre\-bronchodilator clinic measured FEV1 between 40% and 85% of predicted normal.
- •2\. One year history of asthma diagnosed by a physician, and have FEV1 reversibility of 12% and an absolute change of at least 200 mL after administration of 400 µg salbutamol.
- •3\. Must be on at least medium dose inhaled corticosteroids and at least one other asthma controller medication for at least one year.
- •4\. Must have documented history of two or more severe asthma exacerbations in the last 12 months or severe asthma exacerbation in the last 12 months with hospitalization or one exacerbation in the last 6 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 170
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 30
Exclusion Criteria
- •1\. Patients with a significant disease other than asthma.
- •2\. Patients who are not able to produce sputum or sputum samples of sufficient quality.
- •3\. Patients who had clinically relevant history of intubation for asthma exacerbation in the past year.
- •4\. Patients diagnosed with any concurrent respiratory disease.
- •5\. Recent history (within 6 months) of myocardial infarction or hospitalized for cardiac failure in the past year.
- •6\. Patients who have undergone thoracotomy with pulmonary resection.
- •7\. Patients who have undergone bronchial thermoplasty or radiotherapy procedure in the past year or have planned procedures during the study.
- •8\. Patients taking oral corticosteroids with a total daily dose of more than 20 mg prednisone (or equivalent) in the past 6 weeks.
- •9\. Pregnant or nursing women.
- •10\. Women of childbearing potential that, if sexually active, is unwilling to use a highly effective method of birth control.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Efficacy and safety of BI 655066 in patients with severe persistent asthmaEUCTR2014-004932-20-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.369
Active, not recruiting
Phase 1
Efficacy and safety of BI 655066 (risankizumab) in patients with severe persistent asthma.EUCTR2014-004932-20-GBBoehringer Ingelheim Limited200
Active, not recruiting
Not Applicable
Efficacy and safety of BI 655066 in patients with severe persistent asthma.Severe AsthmaTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2014-004932-20-HUBoehringer Ingelheim RCV GmbH & CoKG450
Completed
Phase 2
A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 weeks in patients with severe persistent asthma.Severe asthma10038716NL-OMON45129Boehringer Ingelheim3
Active, not recruiting
Phase 1
Efficacy and safety of BI 655066 (risankizumab) in patients with severe persistent asthma.EUCTR2014-004932-20-BESCS Boehringer Ingelheim Comm.V200